Epinephrine

Highest phase reached
Approved
www.ebi.ac.uk
Drug type
Small molecule
www.ebi.ac.uk
First approval year
1965
www.ebi.ac.uk

First approval year
1965
www.ebi.ac.uk
Listing at source
Listed
Highest phase reached
Approved
www.ebi.ac.uk

Drug type
Small molecule
www.ebi.ac.uk
Drug name
Epinephrine
www.ebi.ac.uk
Molecular weight
183.21
www.ebi.ac.uk
Structure (SMILES)
CNC[C@H](O)c1ccc(O)c(O)c1
www.ebi.ac.uk

  • adren co
  • Adren co
  • adrenaclick
  • Adrenaclick
  • adrenalin
  • Adrenalin
  • ana guard
  • ana kit
  • Ana-guard
  • Ana-kit
  • anapen
  • Anapen
  • anaphylactic shock drug kit
  • Anaphylactic shock drug kit
  • asma vydrin
  • Asma-vydrin
  • asthmahaler
  • Asthmahaler
  • auvi q
  • Auvi-q
  • bronkaid mist
  • Bronkaid mist
  • brovon
  • Brovon
  • emerade

And 55 more, listed on the interactive page.

  • "Epinephrine"
  • (-)-(r)-epinephrine
  • (-)-epinephrine
  • 1 2 benzenediol 4 1 hydroxy 2 methylamino ethyl r
  • 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-
  • adrenaline
  • Adrenaline
  • ADRENALINE [EP IMPURITY]
  • ADRENALINE [EP MONOGRAPH]
  • ADRENALINE [JAN]
  • ADRENALINE [MART.]
  • adrenaline ep impurity
  • adrenaline ep monograph
  • adrenaline jan
  • adrenaline mart
  • adrenalinum
  • Adrenalinum
  • ADRENALINUM [HPUS]
  • adrenalinum hpus
  • anapen
  • conventional does aspirin
  • conventional plus uc msc
  • conventional-does aspirin
  • emerade 300mcg
  • Emerade 300mcg

And 91 more, listed on the interactive page.

CAS registry numbers
  • 51-43-4
ChEMBL ID
CHEMBL679
www.ebi.ac.uk
InChIKey
UCTWMZQNUQWSLP-VIFPVBQESA-N
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • YKH834O4BH

  • A01AD01
  • B02BC09
  • C01CA24
  • R01AA14
  • R03AA01
  • R03AK01
  • S01EA01
  • S01EA51
Sources for recorded values
www.ebi.ac.uk

  • 5816
  • 139148732

  • 362
  • 3992
  • 1249590

Applicant
VIATRIS
Approval date
22 Dec 1987
Application number
NDA019430

Status
Authorised
Status date
22 Aug 2024
Authorisation date
22 Aug 2024
Approved indications
Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more.
Product number
EMEA/H/C/006139
Authorisation holder
ALK-Abelló A/S
Priority medicines scheme
No
Generic
No
Biosimilar
No
Generic medicines
0
Biosimilar medicines
0
Advanced therapy
No
Conditional approval
No
Additional monitoring
No
Accelerated assessment
No
Exceptional circumstances
No

Therapeutic areas

  • Anaphylaxis
European medicines record
www.ema.europa.eu

Patents
31
Designations
0
Earliest recorded loss of exclusivity
17 Jan 2045
First in class
No
Fast track
No
Breakthrough designation
No
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No
Availability
Over the counter

United States (FDA)
Approved
European Union (EMA)
Authorised

Pharmacology name
(-)-adrenaline
Type
Metabolite
Approval recorded by Guide to Pharmacology
Yes

Administration routes

  • Parenteral
  • topical

  • Action type
    ACTIVATION
    Target
    carbonic anhydrase 1
    Gene symbol
    carbonic anhydrase 1
  • Action
    Activation
    Action type
    ACTIVATION
    Target
    carbonic anhydrase 1
    Gene symbol
    CA1
    Protein identifier
    P00915
  • Action type
    Agonist
    Target
    &beta;<sub>1</sub>-adrenoceptor
    Gene symbol
    &beta;<sub>1</sub>-adrenoceptor
  • Action
    Agonist
    Action type
    Agonist
    Target
    β1-adrenoceptor
    Gene symbol
    ADRB1
    Protein identifier
    P08588
    Affinity units
    pEC50
  • Action
    Agonist
    Action type
    Agonist
    Target
    β1-adrenoceptor
    Gene symbol
    ADRB1
    Protein identifier
    P08588
    Affinity units
    pKi
  • Action
    Agonist
    Action type
    Agonist
    Target
    β3-adrenoceptor
    Gene symbol
    ADRB3
    Protein identifier
    P13945
    Affinity units
    pEC50
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P07550
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P08588
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P08913
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P13945
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P18089
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P18825
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P25100
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P35348
  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor
    Protein identifier
    P35368
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>1A</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>1A</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>1B</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>1B</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>1D</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>1D</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>2A</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>2A</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>2B</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>2B</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &alpha;<sub>2C</sub>-adrenoceptor
    Gene symbol
    &alpha;<sub>2C</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &beta;<sub>2</sub>-adrenoceptor
    Gene symbol
    &beta;<sub>2</sub>-adrenoceptor
  • Action type
    FULL_AGONIST
    Target
    &beta;<sub>3</sub>-adrenoceptor
    Gene symbol
    &beta;<sub>3</sub>-adrenoceptor
  • Action
    Full agonist
    Action type
    FULL_AGONIST
    Target
    β2-adrenoceptor
    Gene symbol
    ADRB2
    Protein identifier
    P07550
    Affinity units
    pEC50
  • Action
    Full agonist
    Action type
    FULL_AGONIST
    Target
    β2-adrenoceptor
    Gene symbol
    ADRB2
    Protein identifier
    P07550
    Median affinity
    7.9
    Affinity units
    pEC50

And 17 more, listed on the interactive page.

Open Targets mechanisms

  • Mechanism
    Adrenergic receptor agonist
    Action type
    Agonist
    Target
    Adrenergic receptor

  • Action type
    Agonist
    Gene symbol
    ADRB2
    Protein identifier
    P07550
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA2A
    Protein identifier
    P08913
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA2B
    Protein identifier
    P18089
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA2C
    Protein identifier
    P18825
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA1D
    Protein identifier
    P25100
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA1A
    Protein identifier
    P35348
    Organism
    Homo sapiens
    Target development level
    Clinical
  • Action type
    Agonist
    Gene symbol
    ADRA1B
    Protein identifier
    P35368
    Organism
    Homo sapiens
    Target development level
    Clinical

  • Condition
    Cardiovascular Diseases
    Highest recorded phase
    4
    Condition identifier
    EFO:0000319
    Subject identifier
    D002318
  • Condition
    Diabetes Mellitus
    Highest recorded phase
    0.5
    Condition identifier
    EFO:0000400
    Subject identifier
    D003920
  • Condition
    Infections
    Highest recorded phase
    1
    Condition identifier
    EFO:0000544
    Subject identifier
    D007239
  • Condition
    Wounds and Injuries
    Highest recorded phase
    2
    Condition identifier
    EFO:0000546
    Subject identifier
    D014947
  • Condition
    Stroke
    Highest recorded phase
    3
    Condition identifier
    EFO:0000712
    Subject identifier
    D020521
  • Condition
    Carcinoma, Non-Small-Cell Lung
    Highest recorded phase
    3
    Condition identifier
    EFO:0003060
    Subject identifier
    D002289
  • Condition
    Heart Failure
    Highest recorded phase
    3
    Condition identifier
    EFO:0003144
    Subject identifier
    D006333
  • Condition
    Pain
    Highest recorded phase
    3
    Condition identifier
    EFO:0003843
    Subject identifier
    D010146
  • Condition
    Epistaxis
    Highest recorded phase
    3
    Condition identifier
    EFO:0003895
    Subject identifier
    D004844
  • Condition
    Fractures, Bone
    Highest recorded phase
    3
    Condition identifier
    EFO:0003931
    Subject identifier
    D050723
  • Condition
    Rhinitis, Allergic, Seasonal
    Highest recorded phase
    4
    Condition identifier
    EFO:0003956
    Subject identifier
    D006255
  • Condition
    Skin Neoplasms
    Highest recorded phase
    0.5
    Condition identifier
    EFO:0004198
    Subject identifier
    D012878
  • Condition
    Hypospadias
    Highest recorded phase
    2
    Condition identifier
    EFO:0004209
    Subject identifier
    D007021
  • Condition
    Heart Arrest
    Highest recorded phase
    4
    Condition identifier
    EFO:0004278
    Subject identifier
    D006323
  • Condition
    Death, Sudden, Cardiac
    Highest recorded phase
    2
    Condition identifier
    EFO:0004278
    Subject identifier
    D016757
  • Condition
    Ventricular Fibrillation
    Highest recorded phase
    2
    Condition identifier
    EFO:0004287
    Subject identifier
    D014693
  • Condition
    Acute Lung Injury
    Highest recorded phase
    2
    Condition identifier
    EFO:0004610
    Subject identifier
    D055371
  • Condition
    Osteoarthritis, Knee
    Highest recorded phase
    3
    Condition identifier
    EFO:0004616
    Subject identifier
    D020370
  • Condition
    Hypotension
    Highest recorded phase
    2
    Condition identifier
    EFO:0005251
    Subject identifier
    D007022
  • Condition
    Tachycardia, Ventricular
    Highest recorded phase
    2
    Condition identifier
    EFO:0005306
    Subject identifier
    D017180
  • Condition
    Urticaria
    Highest recorded phase
    4
    Condition identifier
    EFO:0005531
    Subject identifier
    D014581
  • Condition
    Angioedema
    Highest recorded phase
    4
    Condition identifier
    EFO:0005532
    Subject identifier
    D000799
  • Condition
    Rhinitis, Allergic, Seasonal
    Highest recorded phase
    4
    Condition identifier
    EFO:0005854
    Subject identifier
    D006255
  • Condition
    Shock, Septic
    Highest recorded phase
    4
    Condition identifier
    EFO:0006834
    Subject identifier
    D012772
  • Condition
    Appendicitis
    Highest recorded phase
    2
    Condition identifier
    EFO:0007149
    Subject identifier
    D001064

And 33 more, listed on the interactive page.

  • Condition identifier
    EFO_0000319
  • Condition identifier
    EFO_0000400
  • Condition identifier
    EFO_0000544
    Highest recorded phase
    1
  • Condition identifier
    EFO_0000546
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000712
    Highest recorded phase
    3
  • Condition identifier
    EFO_0000714
    Highest recorded phase
    2
  • Condition identifier
    EFO_0003060
    Highest recorded phase
    3
  • Condition identifier
    EFO_0003144
    Highest recorded phase
    3
  • Condition identifier
    EFO_0003895
    Highest recorded phase
    2
  • Condition identifier
    EFO_0003895
    Highest recorded phase
    3
  • Condition identifier
    EFO_0003931
    Highest recorded phase
    3
  • Condition identifier
    EFO_0003956
  • Condition identifier
    EFO_0003957
  • Condition identifier
    EFO_0004198
  • Condition identifier
    EFO_0004209
  • Condition identifier
    EFO_0004278
  • Condition identifier
    EFO_0004278
    Highest recorded phase
    4
  • Condition identifier
    EFO_0004610
    Highest recorded phase
    2
  • Condition identifier
    EFO_0004616
    Highest recorded phase
    3
  • Condition identifier
    EFO_0005251
    Highest recorded phase
    2
  • Condition identifier
    EFO_0005531
  • Condition identifier
    EFO_0005532
  • Condition identifier
    EFO_0005854
  • Condition identifier
    EFO_0006834
  • Condition identifier
    EFO_0006834
    Highest recorded phase
    4

And 87 more, listed on the interactive page.

  • Event
    accidental exposure to product by child
    Reports
    48
    Reporting signal score
    122.091
  • Event
    accidental needle stick
    Reports
    15
    Reporting signal score
    55.7403
  • Event
    acute myocardial infarction
    Reports
    67
    Reporting signal score
    71.1426
  • Event
    airway peak pressure increased
    Reports
    14
    Reporting signal score
    60.071
  • Event
    anaesthetic complication
    Reports
    34
    Reporting signal score
    86.9493
  • Event
    anaphylactic reaction
    Reports
    182
    Reporting signal score
    236.715
  • Event
    angioedema
    Reports
    91
    Reporting signal score
    66.817
  • Event
    arteriospasm coronary
    Reports
    82
    Reporting signal score
    239.393
  • Event
    blood lactic acid increased
    Reports
    34
    Reporting signal score
    68.8717
  • Event
    blood ph decreased
    Reports
    25
    Reporting signal score
    68.1047
  • Event
    bradycardia
    Reports
    145
    Reporting signal score
    136.562
  • Event
    cardiac arrest
    Reports
    135
    Reporting signal score
    220.669
  • Event
    cardiogenic shock
    Reports
    97
    Reporting signal score
    226.617
  • Event
    cataract operation complication
    Reports
    17
    Reporting signal score
    63.4874
  • Event
    circulatory collapse
    Reports
    44
    Reporting signal score
    57.1933
  • Event
    device use issue
    Reports
    41
    Reporting signal score
    94.1891
  • Event
    diarrhoea
    Reports
    15
    Reporting signal score
    109.738
  • Event
    drug hypersensitivity
    Reports
    394
    Reporting signal score
    341.469
  • Event
    electrocardiogram st segment depression
    Reports
    45
    Reporting signal score
    129.114
  • Event
    electrocardiogram st segment elevation
    Reports
    58
    Reporting signal score
    153.427
  • Event
    expired drug administered
    Reports
    43
    Reporting signal score
    136.511
  • Event
    extremity necrosis
    Reports
    30
    Reporting signal score
    87.5601
  • Event
    fall
    Reports
    8
    Reporting signal score
    58.5074
  • Event
    fatigue
    Reports
    43
    Reporting signal score
    69.904
  • Event
    gangrene
    Reports
    26
    Reporting signal score
    53.6275

And 43 more, listed on the interactive page.

And 66 more, listed on the interactive page.

Dose
15-20mL (per procedure, 225-300mg)
Route
Parenteral (intravenous, epidural, caudal)
How often
As needed

  • Administer slowly
  • Aspirate before and during injection
  • Use in dilute solutions (1.5% or 2%) in incremental doses of 3-5mL

Hydrogen bond acceptors
4
Hydrogen bond donors
4
Polar surface area
72.72
Calculated partition coefficient (ALogP)
0.35
Calculated partition coefficient (XLogP)
-1.4
Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Rule-of-five violations
0
Rotatable bonds
3
Heavy atoms
13
Molecular formula
C9H13NO3
Monoisotopic mass
183.08954328
Natural product
Yes

  • 0093-5985
  • 0093-5986
  • 0115-1694
  • 0115-1695
  • 0143-9476
  • 0220-0078
  • 0404-9788
  • 0404-9792
  • 0404-9806
  • 0404-9810
  • 0404-9857
  • 0404-9886
  • 0404-9891
  • 0404-9896
  • 0409-0007
  • 0409-0147
  • 0409-1209
  • 0409-3177
  • 0409-3178
  • 0409-3181
  • 0409-3182
  • 0409-3183
  • 0517-1171
  • 0517-3030
  • 42023-159

And 106 more, listed on the interactive page.

Recorded assays
4,508
Active assays
244

  • Confirmatory
  • Other
  • Screening
  • Summary

Distribution coefficient (LogD)

Median
-3.04
Mean
-3.04
Minimum
-3.49
Maximum
-2.59
Unit
unitless
Assays
2
Standard deviation
0.636396
Summary method
median
Censored results excluded
0
Other units excluded
0
Unknown units excluded
0

Measurement types

  • LogD

Related records

Trials (382)

Approved for (13)

In development for (37)

Other linked conditions (13)

Targets (10)